<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04060836</url>
  </required_header>
  <id_info>
    <org_study_id>CTTQ-NXBYZ-02-PK</org_study_id>
    <nct_id>NCT04060836</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.</brief_title>
  <official_title>Randomized, Open-label, Double Cycle, Crossover, Pharmacokinetics Study of Recombinant Coagulation Factor VIII Injection Versus Xyntha® in Subjects With Hemophilia A.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, open-label, randomized study. Participants will be assigned to A or B
      groups with a scale of 1:1 , i.e. infuse study drug followed by Xyntha (group A), or the
      alternate sequence (group B). All participants who completed the study will enter the
      Prophylactic Therapy Study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters between test preparation and reference preparation, peak plasma concentration (Cmax)</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>Cmax is the maximum plasma concentration of Recombinant Coagulation Factor VIII or metabolite(s).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters between Recombinant Coagulation Factor VIII, Area under the plasma concentration verus time curve(AUC)</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incremental recovery between test preparation and reference preparation</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Peak activity of FVIII (as Cmax) measured within 1 hour after the end of infusion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of time to reach maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on multiple dose in day 5 to day 8.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time of residence (MRT)</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>MRT is the average time that drug molecules stay in the body after a quick intravenous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of terminal rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of apparent plasma clearance following intravenous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on single dose in day 1 to day 4.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of apparent volume of distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration verus time curve (AUC)</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on multiple dose in day 5 to day 8.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Hour 30min (pre-dose), 5min, 20min, 35min, 60min, 1.5 h, 2h, 3 h, 6 h, 9 h, 24 h, 36 h, 48 h post-dose on multiple dose in day 5 to day 8.</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recombinant Coagulation Factor VIII multiple dose:tmax</measure>
    <time_frame>On the 176th day after the prevention of medication</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recombinant Coagulation Factor VIII multiple dose:t1/2</measure>
    <time_frame>On the 176th day after the prevention of medication</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of half-life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recombinant Coagulation Factor VIII multiple dose:λz</measure>
    <time_frame>On the 176th day after the prevention of medication</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of terminal rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recombinant Coagulation Factor VIII multiple dose:CL</measure>
    <time_frame>On the 176th day after the prevention of medication</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of apparent plasma clearance following intravenous injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recombinant Coagulation Factor VIII multiple dose:Vz</measure>
    <time_frame>On the 176th day after the prevention of medication</time_frame>
    <description>To characterize the pharmacokinetics of Recombinant Coagulation Factor VIII by assessment of apparent volume of distribution.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse reference drug Xyntha (group A), then experimental drug (group B). All participants who completed the study will enter the prophylaxis group study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to group A or B with a scale of 1:1 , i.e. infuse experimental drug (group B), then reference drug Xyntha (group A). All participants who completed the study will enter the prophylaxis group study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xyntha</intervention_name>
    <description>Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Coagulation Factor VIII Injection</intervention_name>
    <description>A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hemophilia A.

          2. FVIII:C &lt;1%. 3）12 and 65 years old.

        4）Has received FVIII treatment and the treatment exposure days ≥100. 5）Has bleeding
        treatment records of at least 3 months before randomization. 6）FVIII inhibitor assay
        results is negative.

        7） Subjects should agree to use an adequate method of contraception during the study.

        8）Understood and Signed an informed consent form. 9）Has not received an treatment of any
        FVIII within 4 days before the first dose.

        10）Non-bleeding state.

        Exclusion Criteria:

          1. Has a history or family history of blood coagulation factor VIII inhibitor.

          2. Has other coagulation dysfunction diseases in addition to hemophilia A.

          3. HIV positive.

          4. Plan to receive surgery during the trial.

          5. Has used immunomodulator within one weeks before the first dose，and less than 7
             half-life periods.

          6. Known to be allergic to experimental drugs or any excipients.

          7. Severe anemia and need blood transfusion.

          8. Serious liver or kidney damage.

          9. Serious heart disease.

         10. Uncontrollable hypertension.

         11. Has participated in other clinical studies within one month before the first dose.

         12. The researchers believe that it is not suitable for participants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lei Zhang, Doctor</last_name>
    <phone>022-20909240</phone>
    <email>zhanglei1@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>AnHui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zimin Sun, Doctor</last_name>
      <phone>0551 -62283191</phone>
      <email>zmsun_vip@163.com</email>
    </contact>
    <investigator>
      <last_name>Zimin Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of LanZhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Xi, Doctor</last_name>
      <phone>0931-8356266</phone>
      <email>xiyaming@163.com</email>
    </contact>
    <investigator>
      <last_name>Yaming Xi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HeNan Cancer Provincial Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hu Zhou, Doctor</last_name>
      <phone>0371-65587278</phone>
      <email>&quot;papertigerhu@163.com</email>
    </contact>
    <investigator>
      <last_name>Hu Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xielan Zhao, Doctor</last_name>
      <phone>0731-84327564</phone>
      <email>zhaoxl9198@163.com</email>
    </contact>
    <investigator>
      <last_name>Xielan Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Zhang, Doctor</last_name>
      <phone>022-20909240</phone>
      <email>zhanglei1@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Lei Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2019</study_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

